C12N 2770/32332
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2770/32332 (Use of virus as therapeutic agent, other than vaccine) appears on 25 US grants and 53 published applications in this corpus.
Search patents in C12N- Granted patents
- 25
- Published applications
- 53
- Assignees
- 24
- Inventors
- 88
- Latest grant
- 13 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 3 |
| 2009 | 1 | 2 |
| 2010 | 0 | 4 |
| 2011 | 1 | 1 |
| 2012 | 3 | 2 |
| 2013 | 0 | 2 |
| 2014 | 2 | 0 |
| 2015 | 0 | 3 |
| 2016 | 0 | 4 |
| 2017 | 0 | 2 |
| 2018 | 2 | 2 |
| 2019 | 2 | 7 |
| 2020 | 2 | 6 |
| 2021 | 1 | 3 |
| 2022 | 3 | 6 |
| 2023 | 2 | 1 |
| 2024 | 2 | 2 |
| 2025 | 2 | 2 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Optimized oncolytic viruses and uses thereof13 Jan 2026US 12,521,424 B2Sator Therapeutics
- Antitumor virus30 Dec 2025US 12,508,291 B2Shanxi Academy of Advanced Research and Innovation
- Optimized oncolytic viruses and uses thereof15 Jul 2025US 12,357,664 B2Sator Therapeutics
- Genetically engineered coxsackievirus, and pharmaceutical composition16 Jul 2024US 12,037,608 B2N.P.T. S.R.L.
- Oncolytic virus growth method and antitumor agent2 Jan 2024US 11,857,584 B2Kabushiki Kaisha Yakult Honsha
- Genetically modified enterovirus vectors with enhanced genomic stability2 Oct 2025US 2025/0304999 A1Virogin Biotech Canada Ltd
- Using infectious nucleic acid to treat cancer7 Aug 2025US 2025/0249053 A1Mayo Foundation for Medical Education and Research
- Mir-375- and mir-1-regulated coxsackievirus b3 has no pancreas and heart toxicity but strong antitumor efficiency in colorectal carcinomas1 Aug 2024US 2024/0252564 A1Technische UniversitäT Berlin
- Encapsulated rna polynucleotides and methods of use11 Apr 2024US 2024/0115636 A1ElevateBio Technologies, Inc.
- Antitumor virus23 Feb 2023US 2023/0057747 A1Shanxi Academy of Advanced Research and Innovation
Most cited
By later US patents
- Attenuated poliovirus5US 8,066,983 B2The Research Foundation of State University of New York · 2011
- Methods for treating malignancies expressing ICAM-1 using coxsackie a group viruses2US 7,361,354 B1Viralytics Limited · 2008
- Gene-modified coxsackievirus1US 10,076,547 B2Kyushu University, National University Corporation · 2018
- Method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis1US 7,485,292 B2Viralytics Limited · 2009
- Modified oncolytic viruses1US 8,114,416 B2Viralytics Limited · 2012